BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ellwanger JH, Kaminski VDL, Chies JAB. CCR5 gene editing – Revisiting pros and cons of CCR5 absence. Infection, Genetics and Evolution 2019;68:218-20. [DOI: 10.1016/j.meegid.2018.12.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Kulmann-Leal B, Ellwanger JH, Chies JAB. CCR5Δ32 in Brazil: Impacts of a European Genetic Variant on a Highly Admixed Population. Front Immunol 2021;12:758358. [PMID: 34956188 DOI: 10.3389/fimmu.2021.758358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Bauss J, Morris M, Shankar R, Olivero R, Buck LN, Stenger CL, Hinds D, Mills J, Eby A, Zagorski JW, Smith C, Cline S, Hartog NL, Chen B, Huss J, Carcillo JA, Rajasekaran S, Bupp CP, Prokop JW. CCR5 and Biological Complexity: The Need for Data Integration and Educational Materials to Address Genetic/Biological Reductionism at the Interface of Ethical, Legal, and Social Implications. Front Immunol 2021;12:790041. [PMID: 34925370 DOI: 10.3389/fimmu.2021.790041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Hemmatazad H, Berger MD. CCR5 is a potential therapeutic target for cancer. Expert Opin Ther Targets 2021;25:311-27. [PMID: 33719836 DOI: 10.1080/14728222.2021.1902505] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
4 Ellwanger JH, Kulmann-Leal B, Kaminski VL, Rodrigues AG, Bragatte MAS, Chies JAB. Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases. Virus Res 2020;286:198040. [PMID: 32479976 DOI: 10.1016/j.virusres.2020.198040] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
5 Lee J, Bayarsaikhan D, Bayarsaikhan G, Kim J, Schwarzbach E, Lee B. Recent advances in genome editing of stem cells for drug discovery and therapeutic application. Pharmacology & Therapeutics 2020;209:107501. [DOI: 10.1016/j.pharmthera.2020.107501] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
6 Ellwanger JH, Kaminski VL, Rodrigues AG, Kulmann-Leal B, Chies JAB. CCR5 and CCR5Δ32 in bacterial and parasitic infections: Thinking chemokine receptors outside the HIV box. Int J Immunogenet 2020;47:261-85. [PMID: 32212259 DOI: 10.1111/iji.12485] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
7 Ellwanger JH, Kulmann-Leal B, Wolf JM, Michita RT, Simon D, Lunge VR, Chies JAB. Role of the genetic variant CCR5Δ32 in HBV infection and HBV/HIV co-infection. Virus Res 2020;277:197838. [PMID: 31837381 DOI: 10.1016/j.virusres.2019.197838] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
8 Kulmann-Leal B, Ellwanger JH, Chies JAB. A functional interaction between the CCR5 and CD34 molecules expressed in hematopoietic cells can support (or even promote) the development of cancer. Hematol Transfus Cell Ther 2020;42:70-6. [PMID: 31822447 DOI: 10.1016/j.htct.2019.10.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
9 Ellwanger JH, Kaminski VL, Chies JA. What we say and what we mean when we say redundancy and robustness of the chemokine system - how CCR5 challenges these concepts. Immunol Cell Biol 2020;98:22-7. [PMID: 31613403 DOI: 10.1111/imcb.12291] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
10 Ellwanger JH, Chies JAB. Host genetic factors can impact vaccine immunogenicity and effectiveness. Lancet Infect Dis 2019;19:359-60. [PMID: 30938297 DOI: 10.1016/S1473-3099(19)30121-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]